Frederick National Laboratory for Cancer Research Is Evaluating Resolution Bioscience’s cfDNA Platform for Use in Clinical Trials

SEATTLE — Resolution Bioscience, Inc. today announced that it has entered into an agreement with the Leidos Biomedical Research Inc, which operates the Frederick National Laboratory for Cancer Research, to evaluate Resolution Bio’s ctDx™ novel chemistry and proprietary bioinformatics data analysis pipeline. The agreement includes training of the Frederick National Laboratory’s scientific staff, an effort that is already underway, as well as potential publication of results.

“We are evaluating liquid biopsy technologies that can be used to detect all forms of actionable mutations from clinical specimens,” said Jason Lih, head of the Frederick National Laboratory’s Molecular Characterization Lab.

“We are excited to bring our platform to the Frederick National Laboratory,” said Mark Li, CEO, Resolution Bioscience. “The ctDx technology has demonstrated the abil